These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 3110700)

  • 1. Desferrioxamine infusion test.
    Gilli P; Malacarne F; Storari A; Brancaccio D; Gallieni M; Andriani M; Piccoli A; Nordio M
    Nephrol Dial Transplant; 1987; 2(1):54-5. PubMed ID: 3110700
    [No Abstract]   [Full Text] [Related]  

  • 2. Desferrioxamine infusion test.
    Soler Amigo J; Modol Gort J; Garcia Aznar A
    Nephrol Dial Transplant; 1987; 2(5):381. PubMed ID: 3122122
    [No Abstract]   [Full Text] [Related]  

  • 3. Aluminum accumulation in children on chronic dialysis: predictive value of serum aluminum levels and desferrioxamine infusion test.
    Roodhooft AM; van de Vyver FL; D'Haese PC; van Acker KJ; Visser WJ; de Broe ME
    Clin Nephrol; 1987 Sep; 28(3):125-9. PubMed ID: 3665205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indirect methods for the diagnosis of aluminum bone disease: plasma aluminum, the desferrioxamine infusion test, and serum iPTH.
    Nebeker HG; Andress DL; Milliner DS; Ott SM; Alfrey AC; Slatopolsky EA; Sherrard DJ; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S96-9. PubMed ID: 3458006
    [No Abstract]   [Full Text] [Related]  

  • 5. [Tissue overload of aluminum in hemodialysis patients. The desferrioxamine test].
    Simon P; Ang KS; Tanquerel T; Allain P; Mauras Y
    Nouv Presse Med; 1982 Jan; 11(3):209. PubMed ID: 7058145
    [No Abstract]   [Full Text] [Related]  

  • 6. Comment on "Irreversible ocular toxicity from single challenge dose of desferrioxamine" by C. Bene et al.
    Yaqoob M; Prabhu P; Ahmad R
    Clin Nephrol; 1991 Sep; 36(3):155. PubMed ID: 1934674
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of desferrioxamine on aluminum kinetics during hemodialysis.
    Stummvoll HK; Graf H; Meisinger V
    Miner Electrolyte Metab; 1984; 10(4):263-6. PubMed ID: 6749073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
    Sprague SM; Corwin HL; Wilson RS; Mayor GH; Tanner CM
    Arch Intern Med; 1986 Oct; 146(10):2063-4. PubMed ID: 3767553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma aluminum and iron kinetics in hemodialyzed patients after i.v. infusion of desferrioxamine.
    Ciancioni C; Poignet JL; Mauras Y; Panthier G; Delons S; Allain P; Man NK
    Trans Am Soc Artif Intern Organs; 1984; 30():479-82. PubMed ID: 6533925
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of aluminium intoxication: a new scheme for desferrioxamine administration.
    Douthat WG; Acuña Aguerre G; Fernández Martín JL; Mouzo R; Cannata Andía JB
    Nephrol Dial Transplant; 1994; 9(10):1431-4. PubMed ID: 7816256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between serum aluminum concentration and signs of encephalopathy in a large population of patients dialyzed with aluminum-free fluids.
    Rovelli E; Luciani L; Pagani C; Albonico C; Colleoni N; D'Amico G
    Clin Nephrol; 1988 Jun; 29(6):294-8. PubMed ID: 3396232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of low aluminum water and desferrioxamine on the outcome of dialysis encephalopathy.
    Milne FJ; Sharf B; Bell P; Meyers AM
    Clin Nephrol; 1983 Oct; 20(4):202-7. PubMed ID: 6641027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of aluminum to neurocognitive dysfunction in chronic dialysis patients.
    Sprague SM; Corwin HL; Tanner CM; Wilson RS; Green BJ; Goetz CG
    Arch Intern Med; 1988 Oct; 148(10):2169-72. PubMed ID: 3178374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desferrioxamine in the treatment of aluminum overload.
    Ackrill P; Day JP
    Clin Nephrol; 1985; 24 Suppl 1():S94-7. PubMed ID: 3842106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deferoxamine (DFO): the effectiveness for noninvasive diagnosis of aluminum-related bone disease, and for treatment of the disease.
    Marumo F; Umetani N; Sato N; Takahashi Y
    J UOEH; 1987 Mar; 9 Suppl():140-52. PubMed ID: 3602745
    [No Abstract]   [Full Text] [Related]  

  • 16. Clearance of aluminum by hemodialysis: effect of desferrioxamine.
    Milliner DS; Hercz G; Miller JH; Shinaberger JH; Nissenson AR; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S100-3. PubMed ID: 3457984
    [No Abstract]   [Full Text] [Related]  

  • 17. Is it time to reexamine KDOQI aluminum guidelines?
    Diskin CJ; Thomas CE
    Am J Kidney Dis; 2006 Nov; 48(5):876-7. PubMed ID: 17060012
    [No Abstract]   [Full Text] [Related]  

  • 18. Continuous ambulatory EEG monitoring following desferrioxamine (DFO) i.v. infusion.
    Poignet JL; Monge MF; Ciancioni C; Mikol F; Naret C; Delons S; Man NK
    Trans Am Soc Artif Intern Organs; 1985; 31():546-51. PubMed ID: 3837504
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of a desferrioxamine "microdose" to chelate aluminum in hemodialysis patients.
    Jorge C; Gil C; Possante M; Catarino MC; Cruz A; Andrade R; Teixeira R; Santos N; Ferreira A
    Clin Nephrol; 1999 Nov; 52(5):335-6. PubMed ID: 10585000
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevention and treatment of aluminum intoxication in chronic renal failure.
    Simon P; Allain P; Ang KS; Cam G; Mauras Y
    Adv Nephrol Necker Hosp; 1985; 14():439-78. PubMed ID: 3919543
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.